Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223

Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy